셀트리온제약

068760KOSDAQ

52.8 / 100

Reference Date: 2026-09-08

Financial Score20.5 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 8.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion Pharma is a pharmaceutical company with KGMP, U.S. cGMP, and EU-GMP certifications, producing specialty and biopharmaceuticals at facilities in Jincheon and Ochang, South Korea. Key products include the liver disease treatment 'Godeks' and biosimilars such as 'Ramsima', 'Omlizumab', 'Stelizumab', and 'Aducanumab'. Sales in 2024 rose 22.9% year-on-year to 4.778 trillion KRW.

Number of Employees

1,006people

Average Salary

77.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

45.46Industry Average 15.000.0Point

3.0x industry avg (risky)

PBR

4.13Industry Average 1.200.0Point

3.4x industry avg (risky)

ROE

9.31Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

9.14Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲17.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.9% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 6.9% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
"셀트리온제약, 모회사 끌어주고 정부정책 밀어주고…목표가 6.1만원"....
IBK투자증권의 매수 의견과 목표주가 상향 조정으로 셀트리온제약의 긍정적 전망이 강조됨.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 40,550Won52-week high 75,70052-week low 38,000

1-month return1.0Point

1m -8.26% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 2Negative 1

Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-27
Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-14
Neutral반기보고서 (2026.06)2026-08-14